Search Results
Your search for ,HOW matches 8289 pages
Showing 5601 - 5650Oncologist’s Guilt
The best part of my day is hearing that little voice yell, “It’s Momma!” as my son rushes to greet me with a hug. It is humbling, and sometimes terrifying, to realize that I brought a little person into the world who is completely dependent on my husband and me for survival. Few would argue...
The Best Oncology Lesson
I was 2 months into my first-year fellowship at Georgetown Lombardi Comprehensive Cancer Center in Washington, DC, when I learned the best oncology lesson of my career. I owned a copy of DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology and had read Cancer Treatment...
George Q. Daley, MD, PhD, Named Dean for Faculty of Medicine at Harvard Medical School
George Q. Daley, MD, PhD, a leader in stem cell science and cancer biology whose work spans the fields of basic science and clinical medicine, will become the next Dean of the Faculty of Medicine at Harvard Medical School. He will begin his duties on January 1, 2017. Dr. Daley is currently...
ESMO Publishes Results of European Consortium Study on the Availability of Antineoplastic Medicines
A major new study has found substantial differences in the formulary availability, out-of-pocket costs, and actual availability of anticancer medicines across Europe. The European Society for Medical Oncology (ESMO) European Consortium Study on the Availability of Antineoplastic Medicines was...
Mastery Learning: A New Paradigm for Oncology Medical Education?
According to William C. McGaghie, PhD, Professor of Medical Education and Professor of Preventive Medicine at Northwestern University Feinberg School of Medicine in Chicago, the principles of today’s clinical medical education are rooted in a 19th century model that is no longer useful in a...
New ASCO-SITC Symposium Dives Into Immuno-Oncology Research and Clinical Care
Advances in the field of immuno-oncology are revolutionizing cancer care. Ongoing progress with immune checkpoint agents, immune system boosts, cancer vaccines, and monoclonal antibodies continues to yield new and exciting results. However, with the benefits of rapid expansion comes the challenge...
New Online Tool Available to Assess the Quality of Your Research Program
Take advantage of the new online version of the ASCO Research Program Quality Assessment Tool, which was developed by the ASCO Research Community Forum to help research sites establish or enhance their internal quality assessment program. The online tool makes it easier than ever for users to gauge ...
ASCO Announces 14 Practices Participating in the 2016 Quality Training Program
On July 14, ASCO announced the 14 practices participating in the 2016 Quality Training Program. The program is designed to train oncology health-care providers to investigate and implement data-driven quality improvement and manage clinical and administrative processes and outcomes. “One of the...
Addressing the Significant Disparities and Barriers to Health Care Experienced by LGBT Cancer Survivors
In 2011, the Institute of Medicine (IOM) published its landmark report “The Health of Lesbian, Gay, Bisexual, and Transgender People: Building a Foundation for Better Understanding,” which recognized the scarcity of research in lesbian, gay, bisexual, and transgender (LGBT) individuals and the...
Study Examines Global Trends in Ovarian Cancer Mortality Rates
Deaths from ovarian cancer fell worldwide between 2002 and 2012, and are predicted to continue to decline in the United States, European Union (EU) and Japan by 2020, according to new research published by Malvezzi et al in Annals of Oncology. The main reason is the use of oral contraceptives and...
ASCO Applauds Bold Recommendations From Cancer Moonshot Blue Ribbon Panel
ASCO commended the Cancer Moonshot Initiative Blue Ribbon Panel for its ambitious recommendations to accelerate progress against cancer. “We applaud the Blue Ribbon Panel for its work and the National Cancer Institute's (NCI's) National Cancer Advisory Board for convening the panel,”...
Weight Watchers and the American Cancer Society Launch Initiative to Support Holistic Health for Breast Cancer Survivors
Weight Watchers International, Inc, has launched Project LIFT—Live Inspired, Fight Together—a new movement, in collaboration with the American Cancer Society, to inspire and guide breast cancer survivors with free resources focused on tackling the unexpected weight gain that can follow breast...
Clinical Trials Actively Recruiting Patients With Basal Cell Carcinoma
Study Title: Long-Pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma (BCC) Study Type: Interventional/single-group assignment Study Sponsor and Collaborators: University of California, San Diego; Massachusetts General Hospital Purpose: To evaluate the safety and efficacy of laser...
Management of Merkel Cell Carcinoma
A recent report regarding pembrolizumab (Keytruda) for advanced Merkel cell carcinoma ushered in a more optimistic era in the treatment of this rare but often lethal skin cancer.1 The ASCO Post spoke with one of the field’s leaders, Paul Nghiem, MD, PhD—the first author of the study—about the...
Use of Pembrolizumab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma After Platinum-Containing Therapy
On August 5, 2016, pembrolizumab (Keytruda) was granted accelerated approval for treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma and disease progression on or after platinum-containing chemotherapy.1,2 As a condition of the accelerated approval, Merck is...
Effect of Radiosurgery Alone vs With Whole-Brain Radiotherapy on Cognitive Function in Patients With Brain Metastases
Physicians from Carolinas HealthCare System’s Neurosciences Institute and Levine Cancer Institute are among the authors of a recent study published by Brown et al in JAMA.1 The study showed how among patients with one to three brain metastases, the use of stereotactic radiosurgery alone, compared...
AACI Names Three New Members to Board of Directors
The Association of American Cancer Institutes (AACI) has announced the election of Karen E. Knudsen, PhD; Norman Sharpless, MD; and Eduardo Sotomayor, MD, to the AACI Board of Directors. The new Directors’ 3-year terms will start on October 23, 2016, during the AACI/ Cancer Center Administrators...
Immune Analysis of On-Treatment Longitudinal Biopsies Predicts Response to Melanoma Immunotherapy
Immune response measured in tumor biopsies during the course of early treatment predicts which melanoma patients will benefit from specific immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center found in a report published by Chen et al in Cancer...
Posttreatment Problems Surveyed in African American Breast Cancer Survivors
Although there is some overlap, past research has shown that the challenges faced by African American breast cancer survivors differ somewhat from Caucasian women. But the studies that demonstrated difference were not designed to explore those challenges in depth. Now new research from Thomas...
Learn How to Implement the Psychosocial Distress Screening Quality Care Standard at the 2017 APOS Annual Conference
The National Cancer Institute (NCI)-funded Psychosocial Distress Program is an educational program desgined to train cancer care clinicians over 2 years to develop, implement, and maintain comprehensive psychosocial distress screening programs. The 1st year of the Screening for Psychosocial...
Predictors of Readmission in Patients Requiring Free Tissue Reconstruction for Head and Neck Cancer
Certain factors increase the risk of unplanned readmission in the month after head and neck cancer resection requiring free tissue reconstruction, finds an analysis of data from the National Surgical Quality Improvement Program (NSQIP) of the American College of Surgeons.1 Nearly 1 in 10 patients...
Expert Point of View: M. Boyd Gillespie, MD, MSCR
“This study is actually surprising to me, because earlier studies of that particular antibody as a single therapy for this disease, salivary duct carcinoma, showed it was not very effective, with only 10% to 15% response rates,” session co-moderator, M. Boyd Gillespie, MD, MSCR, Professor and Vice ...
Use of Lugol’s Iodine Stain May Reduce the Need for Repeat Resection of Oral and Oropharyngeal Cancers
By identifying residual dysplasia in the tumor bed, Lugol’s iodine staining may improve pathologic outcomes with resection of oral and oropharyngeal cancers, according to interim findings of a UK randomized controlled trial reported at the 9th International Conference on Head and Neck Cancer.1...
Palliative Care 2016: 'Mystery Shopper' Study Finds Barriers to Accessing Palliative Care Services at Major Cancer Centers
A team of researchers, using a novel approach, found that while many cancer centers offer palliative and supportive care services, patients may face challenges when trying to access them. The study showed that expanding awareness and education to patient-facing cancer center employees about such...
Palliative Care 2016: Early Palliative Care Improves Coping, Quality of Life for Patients With Incurable Cancers
A randomized clinical trial found that introducing palliative care shortly after a diagnosis of certain metastatic cancers greatly increases a patient’s coping abilities, as well as overall quality of life. Researchers also found that early integration of palliative care results in an...
Is Human Life Worth No More Than a Text Message?
The words “cost control,” “value-based health care,” and similar iterations are floating around freely these days to make us aware of the unsustainable upward trajectory of health-care costs. We are reminded constantly about how health care in America currently costs more than $3.4 trillion...
Early Relapse in Follicular Lymphoma: Clinical Trial Data May Guide Management Decisions
Approximately 20% of patients with follicular lymphoma will relapse within 2 years of diagnosis. Although the optimal management of these patients has not been established, clinicians may be guided by data from recent clinical trials, according to Nathan H. Fowler, MD, Associate Professor and...
Gene Overexpression Scoring System May Accurately Predict Patient Response to Cancer Treatments
Researchers at the Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) identified 14 genes regulating genome integrity that were consistently overexpressed in a wide variety of cancers. They then created a scoring system based upon the degree of gene overexpression. For...
Accumulation of Metabolite Fumarate May Be Linked to Hereditary Leiomyomatosis and Renal Cell Cancer
Researchers funded by the Medical Research Council (MRC) have shown that when the metabolite fumarate accumulates in a hereditary form of renal cancer, it leads to an epigenetic reprogramming that drives cancer, according to a study published by Sciacovelli et al in Nature. The tumor growth...
PSA-Based Computational Model Predicts Time to Relapse After Prostate Cancer Surgery
Approximately one in four patients who undergo radical prostatectomy experience a cancer recurrence. Now a study by Stura et al investigating a prostate-specific antigen (PSA)-based computational model that uses four consecutive postsurgical PSA values has found the mathematical model to be highly...
Retinoic Acid May Suppress Colorectal Cancer Development
Retinoic acid may play a critical role in suppressing colorectal cancer in mice and humans, according to researchers at the Stanford University School of Medicine. Mice with the cancer have lower-than-normal levels of the metabolite in their gut, the researchers found. Furthermore, colorectal...
Novel MRI Technique Distinguishes Healthy Prostate Tissue From Cancer Using Zinc
A novel magnetic resonance imaging (MRI) method that detects low levels of zinc ion can help distinguish healthy prostate tissue from cancer, The University of Texas (UT) Southwestern Medical Center radiologists have determined. The findings were published by Clavijo Jordan et al in the Proceedings ...
Cancer Research Institute to Honor Three Scientists for Outstanding Contributions to Cancer Immunotherapy Research
The Cancer Research Institute (CRI), a nonprofit organization established in 1953 to advance biomedical research with the goal of developing lifesaving immunotherapies for all forms of cancer, will bestow its highest honors on three scientists who have made fundamental contributions to the fields...
Melanoma MicroRNA Trafficking May Control Tumor Primary Niche Formation
Researchers at Tel Aviv University (TAU) may have unraveled the metastatic mechanism of melanoma. According to a paper published by Dror et al in Nature Cell Biology, scientists discovered that before spreading to other organs, a melanoma tumor sends out tiny vesicles containing molecules of...
ASCO Announces 14 Practices Participating in the 2016 Quality Training Program
On July 14, ASCO announced the 14 practices that are participating in the 2016 Quality Training Program. The program is designed to train oncology health-care providers to investigate and implement data-driven quality improvement and manage clinical and administrative processes and outcomes. “One...
Weight-Management Resource for Patients
ASCO’s booklet Managing Your Weight After a Cancer Diagnosis: A Guide for Patients and Families addresses how being overweight slows recovery and affects survival for patients with cancer. In addition to providing information on different weight-loss methods, this booklet discusses the common...
Four Young Scientists Receive Damon Runyon–Sohn Pediatric Cancer Research Fellowship Awards
The Damon Runyon Cancer Research Foundation has named four outstanding young scientists as recipients of the prestigious Damon Runyon–Sohn Pediatric Cancer Research Fellowship Award, committing nearly $1 million to help address a critical shortage of funding for pediatric cancer research. The...
Clinical Trials Actively Recruiting Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on chronic lymphocytic leukemia. These studies are investigating multiple combination chemotherapies; regimens for relapsed and/or refractory disease; the role of inhibitors;...
Schwartz Center for Compassionate Healthcare Launches New Education and Training Programs
The Schwartz Center for Compassionate Healthcare recently announced the launch of two comprehensive educational offerings informed by the Compassionate, Collaborative Care—“The Triple C”—Framework, a new interdisciplinary model focused on improving quality and outcomes. The new educational...
Surgical Oncologist Quan P. Ly, MD, FACS, Flees From Vietnam and Finds a Home at the University of Nebraska
After the Vietnam War, close to a million refugees, known as “boat people,” fled Vietnam, hazarding the open ocean on dangerously overloaded vessels. The term “boat people” is often used generically to refer to all the Vietnamese (about 2 million) who left their country by any means between 1975...
Six Perspectives on the Cancer Moonshot Goal of Making 10 Years of Progress in 5 Years
The Cancer Moonshot initiative is bringing together scientists, oncologists, patient advocates, and representatives of the biopharmaceutical industry with renewed collaborative focus and the ambitious objective of consolidating 10 years of cancer research in 5 years. Achieving this outcome will...
Study Finds Effect of Combined Hormone Replacement Therapy on Breast Cancer Risk Likely to Have Been Underestimated
The effect of combined hormone replacement therapy (HRT) in increasing a woman’s risk of breast cancer is likely to have been underestimated by a number of previous studies, according to a new prospective study published by Jones et al in the British Journal of Cancer. HRT is used to treat...
ASTRO Awards $275,000 in Grants to Support Early Career Researchers in Radiation Oncology
The American Society for Radiation Oncology (ASTRO) has selected four early career scientists to receive a total of $275,000 in research awards, including one winner of the ASTRO Junior Faculty Career Research Training Award and three recipients of ASTRO Resident/Fellows in Radiation Oncology...
Late Cardiac Effects of Cancer Treatment
The combination of more precise diagnostic tools and advances in surgery, chemotherapy, radiation therapy, and targeted therapy in the treatment of cancer has led to unprecedented numbers of cancer survivors in the United States—more than 15.5 million, according to the latest figures from the...
Outcomes With Rituximab in DLBCL: Does Gender Matter?
For diffuse large B-cell lymphoma, does the dose of rituximab (Rituxan) matter? Are there patient characteristics that determine outcomes as well as the optimal dose? These questions were explored at the 2016 Pan Pacific Lymphoma Conference by Matthew A. Lunning, DO, Assistant Professor of...
AACR Holds Congressional Briefing to Reiterate Moonshot Goals and Plans
“We are in an era of unprecedented scientific opportunities in cancer research,” said Margaret Foti, PhD, MD (hc), Executive Officer, American Association for Cancer Research (AACR), as she introduced the Congressional briefing, “Seizing Today’s Opportunities to Accelerate Cancer Research.” “Thanks ...
ASCO and SGO Release Clinical Practice Guideline on Neoadjuvant Therapy for Newly Diagnosed Advanced Ovarian Cancer
As reported by Alexi A. Wright, MD, MPH, of Dana-Farber Cancer Institute, and colleagues in the Journal of Clinical Oncology, ASCO and the Society of Gynecologic Oncology (SGO) have released a clinical practice guideline on neoadjuvant therapy for patients with newly diagnosed stage IIIC or IV...
Novel Approaches Harness the Microenvironment Against Hodgkin Lymphoma
In the treatment of classical Hodgkin lymphoma, antibodies targeting programmed cell death protein 1 (PD-1) are just the beginning, according to Stephen M. Ansell, MD, PhD, Professor of Medicine and Chair of the Lymphoma Group at the Mayo Clinic, Rochester, Minnesota.1 Speaking at the 2016 Pan...
New Upfront Treatment Algorithm Emerges for Chronic Lymphocytic Leukemia
According to Susan M. O’Brien, MD, an expert in the treatment of chronic lymphocytic leukemia (CLL), novel agents and new data on patient subsets have led to a new upfront treatment algorithm for this malignancy. Speaking at the 2016 Pan Pacific Lymphoma Conference in Koloa, Hawaii, Dr. O’Brien...
How the Oncology Center of Excellence Plans to Foster Collaboration Among Researchers to Advance Cancer Treatment
On June 29, 2016, Robert M. Califf, MD, MACC, the Commissioner of the U.S. Food and Drug Administration (FDA), announced the selection of Richard Pazdur, MD, FACP, as Acting Director of the FDA’s newly created Oncology Center of Excellence. The center was created in response to the overarching...
